Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

被引:0
作者
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构
[1] Jefferson Hospital for Neuroscience,
[2] University of South Alabama College of Medicine,undefined
[3] George Washington School of Medicine,undefined
[4] Allergan plc,undefined
[5] Montefiore Headache Center,undefined
[6] Department of Neurology,undefined
[7] Department of Epidemiology and Population Health,undefined
[8] Albert Einstein College of Medicine,undefined
[9] Headache Center of Southern California,undefined
[10] The Neurology Center,undefined
来源
The Journal of Headache and Pain | 2019年 / 20卷
关键词
COMPEL; Daily headache; Disability; Migraine; OnabotulinumtoxinA; Quality of life;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 174 条
[1]  
Natoli JL(2010)Global prevalence of chronic migraine: a systematic review Cephalalgia 30 599-609
[2]  
Manack A(2007)Migraine comorbidity constellations Headache 47 857-865
[3]  
Dean B(2016)Chronic daily headache: ten steps for primary care providers to regain control Headache 56 1675-1684
[4]  
Butler Q(2005)Predictors of a negative response to topiramate therapy in patients with chronic migraine Headache 45 932-935
[5]  
Turkel CC(2017)Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial Lancet Neurol 16 425-434
[6]  
Stovner L(2017)Fremanezumab for the preventive treatment of chronic migraine N Engl J Med 377 2113-2122
[7]  
Lipton RB(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial Cephalalgia 30 793-803
[8]  
Tietjen GE(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalalgia 30 804-814
[9]  
Herial NA(2010)OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program Headache 50 921-936
[10]  
Hardgrove J(2011)OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program Headache 51 1358-1373